Gene editing therapeutic - NanoVation Therapeutic
Alternative Names: mRNA/gRNA - NanoVation TherapeuticsLatest Information Update: 24 Apr 2026
At a glance
- Originator NanoVation Therapeutics
- Class Gene therapies; RNA
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Unspecified
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 16 Feb 2026 mRNA therapeutic - NanoVation Therapeutic is available for licensing as of 12 Feb 2026. https://nanovationtx.com/partnership-to-enable-gene-therapies/
- 12 Feb 2026 Preclinical trials in Unspecified in Canada (IV) prior to February 2026 (NanoVation Therapeutics pipeline, February 2026)
- 18 Jun 2024 NanoVation Therapeutics has patent protection for 'mRNA delivery composition' in USA